Shares of Evotec SE (ETR: EVT) gained around 2% on Monday after the company said it secured a grant from the Bill & Melinda Gates Foundation.
Evotec will use funds to support its US-based subsidiary Just to work on identifying and developing potential monoclonal antibody drugs for the prevention of severe COVID-19.
“Evotec Biologics will use its proprietary software toolset Abacus™ to perform an in silico analysis of several lead candidate sequences of potent anti-SARS-CoV-2 mAbs provided to the foundation by several leading academic medical centres around the world.
WELCOME BONUS - Free Share Bundle When You Invest £50!
Open a UK Investment Account: Shares, ISAs, Managed Portfolio
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
IG
View Offers
Empfohlener Broker
Multi Asset Platform
“Abacus™ analysis will identify key sequences that can impact developability and, if required, make recommendations to optimise the anti-SARS-CoV-2 antibody candidates. In addition, Just – Evotec Biologics will perform cell line development for two lead molecules,” the company said in a statement.
Antibody drugs came into the spotlight after the U.S. President Donald Trump was treated with a cocktail of Regeneron’s antibody drugs.
Evotec share price gained over 2% to trade at €23.60 today.
PEOPLE WHO READ THIS ALSO VIEWED:
- Here’s Why Just Eat Takeaway Share Price Just Soared to Fresh Record Highs
- Experience stock trading with a reliable demo account
- Implement Divergence Trading strategy in your daily trading plan